Outcomes of metastatic chromophobe renal cell carcinoma (ChRCC) with sarcomatoid features (SF).
Yasser Ged(Memorial Sloan Kettering Cancer Center), Martin H. Voss(Memorial Sloan Kettering Cancer Center), Almedina Redzematovic(Memorial Sloan Kettering Cancer Center), Chung‐Han Lee(Memorial Sloan Kettering Cancer Center), Andrea Knežević(Memorial Sloan Kettering Cancer Center), Ying‐Bei Chen(Memorial Sloan Kettering Cancer Center), Sujata Patil(Kettering University), Maria I. Carlo(Memorial Sloan Kettering Cancer Center), Robert J. Motzer(Memorial Sloan Kettering Cancer Center), Darren R. Feldman(Memorial Sloan Kettering Cancer Center)
Cited by 0
Related Papers
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
|New England Journal of Medicine|2018|4.6k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma
|Cancer Cell|2016|855